Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein

Iliodora Pop, Laurentiu Pop, Ellen S. Vitetta, Maria Ana Ghetie

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objective of this study was to generate new P-glycoprotein (P-gp)-expressing multidrug resistant (MDR) cell lines by drug selection. Since our previous studies have been carried out with cells infected with a P-gp-containing vector, it was important to confirm our findings in cells generated by drug selection. In this report, we describe three B-lymphoma cell lines which became drug-resistant by stepwise exposure to vincristine (VCR): Raji cells resistant to 18 nM VCR (R18V), Namalwa cells resistant to 21 nM VCR (N21V) and DHL-4 cells resistant to 12 nM VCR (DHL-41/12V). Cells overexpressed P-gp and continued to express CD19, CD20 and CD22, all of which are targets for monoclonal antibody (MAb) therapy. The P-gp pump in these new cells was functional as determiped by the efflux of Rhodamine 123 and DIOC2, and the three cell lines were resistant to several chemotherapeutic drugs. We further determined that their P-gp phenotype was stable in xenografted SCID mice and that the tumors were also resistant to chemotherapy. We will now use these new MDR cells to determine whether monoclonal antibodies against CD19 and -20 can reverse P-gp, as we previously demonstrated using Namalwa cells infected with a human mdr1 gene-containing retrovirus.

Original languageEnglish (US)
Pages (from-to)889-895
Number of pages7
JournalOncology Reports
Volume19
Issue number4
StatePublished - Apr 2008

Fingerprint

P-Glycoprotein
Lymphoma
Cell Line
Vincristine
Pharmaceutical Preparations
Monoclonal Antibodies
Rhodamine 123
SCID Mice
Retroviridae
Phenotype
Drug Therapy

Keywords

  • DHL-4 cells
  • Multidrug resistance
  • Namalwa
  • P-glycoprotein
  • Raji

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein. / Pop, Iliodora; Pop, Laurentiu; Vitetta, Ellen S.; Ghetie, Maria Ana.

In: Oncology Reports, Vol. 19, No. 4, 04.2008, p. 889-895.

Research output: Contribution to journalArticle

@article{f49a0664b1594f9882e7e9f864302261,
title = "Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein",
abstract = "The objective of this study was to generate new P-glycoprotein (P-gp)-expressing multidrug resistant (MDR) cell lines by drug selection. Since our previous studies have been carried out with cells infected with a P-gp-containing vector, it was important to confirm our findings in cells generated by drug selection. In this report, we describe three B-lymphoma cell lines which became drug-resistant by stepwise exposure to vincristine (VCR): Raji cells resistant to 18 nM VCR (R18V), Namalwa cells resistant to 21 nM VCR (N21V) and DHL-4 cells resistant to 12 nM VCR (DHL-41/12V). Cells overexpressed P-gp and continued to express CD19, CD20 and CD22, all of which are targets for monoclonal antibody (MAb) therapy. The P-gp pump in these new cells was functional as determiped by the efflux of Rhodamine 123 and DIOC2, and the three cell lines were resistant to several chemotherapeutic drugs. We further determined that their P-gp phenotype was stable in xenografted SCID mice and that the tumors were also resistant to chemotherapy. We will now use these new MDR cells to determine whether monoclonal antibodies against CD19 and -20 can reverse P-gp, as we previously demonstrated using Namalwa cells infected with a human mdr1 gene-containing retrovirus.",
keywords = "DHL-4 cells, Multidrug resistance, Namalwa, P-glycoprotein, Raji",
author = "Iliodora Pop and Laurentiu Pop and Vitetta, {Ellen S.} and Ghetie, {Maria Ana}",
year = "2008",
month = "4",
language = "English (US)",
volume = "19",
pages = "889--895",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein

AU - Pop, Iliodora

AU - Pop, Laurentiu

AU - Vitetta, Ellen S.

AU - Ghetie, Maria Ana

PY - 2008/4

Y1 - 2008/4

N2 - The objective of this study was to generate new P-glycoprotein (P-gp)-expressing multidrug resistant (MDR) cell lines by drug selection. Since our previous studies have been carried out with cells infected with a P-gp-containing vector, it was important to confirm our findings in cells generated by drug selection. In this report, we describe three B-lymphoma cell lines which became drug-resistant by stepwise exposure to vincristine (VCR): Raji cells resistant to 18 nM VCR (R18V), Namalwa cells resistant to 21 nM VCR (N21V) and DHL-4 cells resistant to 12 nM VCR (DHL-41/12V). Cells overexpressed P-gp and continued to express CD19, CD20 and CD22, all of which are targets for monoclonal antibody (MAb) therapy. The P-gp pump in these new cells was functional as determiped by the efflux of Rhodamine 123 and DIOC2, and the three cell lines were resistant to several chemotherapeutic drugs. We further determined that their P-gp phenotype was stable in xenografted SCID mice and that the tumors were also resistant to chemotherapy. We will now use these new MDR cells to determine whether monoclonal antibodies against CD19 and -20 can reverse P-gp, as we previously demonstrated using Namalwa cells infected with a human mdr1 gene-containing retrovirus.

AB - The objective of this study was to generate new P-glycoprotein (P-gp)-expressing multidrug resistant (MDR) cell lines by drug selection. Since our previous studies have been carried out with cells infected with a P-gp-containing vector, it was important to confirm our findings in cells generated by drug selection. In this report, we describe three B-lymphoma cell lines which became drug-resistant by stepwise exposure to vincristine (VCR): Raji cells resistant to 18 nM VCR (R18V), Namalwa cells resistant to 21 nM VCR (N21V) and DHL-4 cells resistant to 12 nM VCR (DHL-41/12V). Cells overexpressed P-gp and continued to express CD19, CD20 and CD22, all of which are targets for monoclonal antibody (MAb) therapy. The P-gp pump in these new cells was functional as determiped by the efflux of Rhodamine 123 and DIOC2, and the three cell lines were resistant to several chemotherapeutic drugs. We further determined that their P-gp phenotype was stable in xenografted SCID mice and that the tumors were also resistant to chemotherapy. We will now use these new MDR cells to determine whether monoclonal antibodies against CD19 and -20 can reverse P-gp, as we previously demonstrated using Namalwa cells infected with a human mdr1 gene-containing retrovirus.

KW - DHL-4 cells

KW - Multidrug resistance

KW - Namalwa

KW - P-glycoprotein

KW - Raji

UR - http://www.scopus.com/inward/record.url?scp=43849107658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43849107658&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 889

EP - 895

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -